Clontech Laboratories, Inc. Partners With Rubicon Genomics To Increase Speed And Efficiency Of Sample Preparation For RNA

 Clontech Laboratories, Inc. Partners With Rubicon Genomics To Increase Speed
           And Efficiency Of Sample Preparation For RNA Sequencing

- Clontech's SMART™ Technology Combined with Rubicon's ThruPLEX™
Pre-Analytical Technology Enables Researchers to Conduct High Quality RNA Seq
Studies from Very Low Amounts of Total RNA -

PR Newswire

MOUNTAIN VIEW, Calif. and ANN ARBOR, Mich., June 6, 2013

MOUNTAIN VIEW, Calif. and ANN ARBOR, Mich., June 6, 2013 /PRNewswire/
--Clontech Laboratories, Inc., a wholly-owned subsidiary of Takara Bio Inc.,
and Rubicon Genomics, Inc. announced today that they have partnered to
integrate Clontech's SMART technology with Rubicon's ThruPLEX technology to
increase the efficiency and quality of RNA sample preparation for a variety of
next generation sequencing (NGS) applications. The launch of the SMARTer^®
Universal Low Input RNA Library Prep Kit, which combines ThruPLEX technology
with Clontech's SMARTer Universal Low Input RNA Kit for Sequencing, provides
an unparalleled solution to generate libraries for transcriptome analysis from
very low amounts of total RNA, including compromised or non-PolyA RNA samples.

There is a need for RNA seq methods that provide accurate transcript
information when sample quantity is limiting — for example, in studies on
single cells or FFPE samples. Clontech's SMARTer Universal Low Input RNA
Library Prep Kit is designed and validated to generate libraries from very low
amounts of compromised RNA, for transcriptome analysis on Illumina^® NGS
instruments. The SMARTer Universal Low Input RNA Library Prep Kit combines the
sensitive and accurate gene coverage of SMART technology with ThruPLEX library
prep technology, making it a powerful tool for RNA seq studies on small
samples of compromised material, e.g. FFPE tissue.

Rubicon's ThruPLEX technology incorporates a streamlined one-tube, three-step
process without intermediate purifications, transfers, columns or gels. The
reduced steps and material transfers decrease the likelihood of experimental
variability, bias and contamination. ThruPLEX technology is designed and
validated for use with samples with very low inputs, between 50 picograms and
50 nanograms of input DNA, and is a perfect partner downstream of the SMARTer
kits for RNA-seq. The technology is currently available for sequencing on
Illumina HiSeq^®, MiSeq^® and Genome Analyzer™ instruments.

"Our SMART technology and Rubicon's ThruPLEX technology are highly
complementary, and we believe that combining the two provides an ideal
solution for RNA sequencing studies using low input RNA samples," said Carol
Lou, General Manager of Clontech. "We are excited to announce the launch of
the SMARTer Universal Low Input RNA Library Prep Kit today, and we will be
launching additional combined products in the coming months."

"The launch of the SMARTer Universal Low Input RNA Library Prep Kit is an
example of our strategy to partner with industry leaders to extend the reach
of our proprietary technology," noted James Koziarz, CEO of Rubicon Genomics.
"Combining ThruPLEX with Clontech's SMARTer sample preparation technologies
for RNA sequencing enables researchers to achieve the highest quality results
for transcriptome analysis."

Clontech plans to continue expanding the use of SMART technology for NGS,
particularly in areas where low sample input is a constraint.

About Clontech Laboratories
Clontech Laboratories, Inc., a wholly-owned subsidiary of Takara Bio Inc.,
develops, manufactures, and distributes a wide range of life science research
reagents under the Clontech^® and Takara brands. Key products include SMARTer
cDNA synthesis kits for a variety of samples and applications, including NGS;
high-performance qPCR and PCR reagents (including theEx Taq^®,LA Taq^®,
Titanium^®, and Advantage^® enzymes); RT enzymes; the innovative In-Fusion^®
cloning system; Tet-based inducible gene expression systems; Living Colors^®
fluorescent proteins and a range of Macherey-Nagel nucleic acid purification
tools. These and other products support applications including NGS, gene
discovery, regulation, and function; protein expression and purification; RNAi
and stem cell studies; and plant and food research. For more information,
visitwww.clontech.com.

About Takara Bio Inc.
Takara Bio Inc. is an innovative biotechnology company based in Shiga, Japan.
As a world leader in biotechnology research and development, Takara Bio was
the first company to market PCR technology in Japan and is also the developer
of the RetroNectin^® reagent, which is used as a world-standard in gene
therapy protocols. In addition to providing research reagents and equipment to
the life science research market, Takara Bio has active research and product
development activities in the fields of gene and cell-based therapy, and
agricultural biotechnology; and is committed to preventing disease and
improving the quality of life for all people through the use of biotechnology.
Through strategic alliances with other industry leaders, Takara Bio aims to
extend its reach around the world. More information is available at
www.takara-bio.com.

About Rubicon Genomics
Rubicon Genomics, Inc. is a leader in the development and commercialization of
sample-specific pre-analytical processes to improve the performance and
capabilities of DNA and RNA analytical platforms for research and clinical
testing. The company's core competency is the creation of more efficient
molecular biology tools for genetic, epigenetic and expression analysis of
difficult clinical samples to facilitate gene-based research, drug
development, diagnostics and forensics. Privately held Rubicon Genomics is
located in Ann Arbor, Michigan. For more information, visit
www.rubicongenomics.com.

SOURCE Clontech Laboratories, Inc.

Website: http://www.clontech.com
Contact: Clontech Laboratories, Inc., Lorna Neilson, Ph.D., Director, Business
Development, Clontech Laboratories, Inc., 1290 Terra Bella Avenue, Mountain
View, CA 94043, Tel: 650.919.7372, Email: lorna_neilson@clontech.com or
Rubicon Genomics, Inc., James Koziarz, Ph.D., Chief Executive Officer, Rubicon
Genomics, Inc., 4355 Varsity Drive, Suite E, Ann Arbor, MI 48108, Tel:
734.677.4845, Email: jkoziarz@rubicongenomics.com, or Rubicon Media, Barbara
Lindheim, BLL Partners, LLC, blindheim@bllbiopartners.com, 212.584.2276